CAPN9 and gastric cancer: Our data suggested that calpain-9 could be useful as a new biomarker to establish the risk and prognosis of gastric cancer and to facilitate the selection of therapeutic modalities in clinical practice, as well as to propose a strategy to target calpain-9 as a potential adjuvant therapy for gastric cancer treatment.